For example, chronic treatment with FGF-23 antibodies for 6 weeks in an experimental CKD rat model improved secondary hyperparathyroidism by decreasing PTH and increasing vitamin D, but phosphate levels, aortic calcification and even mortality were significantly increased (Shalhoub et al., 2012). Here, PTH is linked to chronic kidney disease.